Evidence map›Paper›PMID 36429090›Full record

ArticleCells2022

Antibody Levels Poorly Reflect on the Frequency of Memory B Cells Generated following SARS-CoV-2, Seasonal Influenza, or EBV Infection.

Carla Wolf, Sebastian Köppert, Noémi Becza, Stefanie Kuerten, Greg A Kirchenbaum, Paul V Lehmann

Abstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Extending ImmunoSpotVaccines · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carla WolfResearch and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA.
Sebastian KöppertResearch and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA.
Noémi BeczaResearch and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA.
Stefanie KuertenInstitute of Anatomy and Cell Biology, Friedrich-Alexander University Erlangen-Nürnberg, 91054 Erlangen, Germany.ORCID 0000-0001-6119-605X
Greg A KirchenbaumResearch and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA.ORCID 0000-0001-6463-7623
Paul V LehmannResearch and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The scope of immune monitoring is to define the existence, magnitude, and quality of immune mechanisms operational in a host. In clinical trials and praxis, the assessment of humoral immunity is commonly confined to measurements of serum antibody reactivity without accounting for the memory B cell potential. Relying on fundamentally different mechanisms, however, passive immunity conveyed by pre-existing antibodies needs to be distinguished from active B cell memory. Here, we tested whether, in healthy human individuals, the antibody titers to SARS-CoV-2, seasonal influenza, or Epstein-Barr virus antigens correlated with the frequency of recirculating memory B cells reactive with the respective antigens. Weak correlations were found. The data suggest that the assessment of humoral immunity by measurement of antibody levels does not reflect on memory B cell frequencies and thus an individual's potential to engage in an anamnestic antibody response against the same or an antigenically related virus. Direct monitoring of the antigen-reactive memory B cell compartment is both required and feasible towards that goal.

Indexed as

COVID-19Epstein-Barr Virus InfectionsInfluenza, HumanAntibodies, ViralHerpesvirus 4, HumanHumansMemory B CellsSARS-CoV-2SeasonsAntibodies, Viralaffinity maturationantibody-mediated immunityEBVELISPOTFluoroSpotimmune monitoringinfluenzamemory B cellsplasma cellsSARS-CoV-2

Identifiers

PMID36429090
PMCPMC9688940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.